{"id":3027,"date":"2026-01-08T06:39:04","date_gmt":"2026-01-08T06:39:04","guid":{"rendered":"https:\/\/joyzymebiotech.com\/aboutus\/"},"modified":"2026-02-06T03:26:33","modified_gmt":"2026-02-06T03:26:33","slug":"aboutus","status":"publish","type":"page","link":"https:\/\/joyzymebiotech.com\/en\/aboutus\/","title":{"rendered":"About Us"},"content":{"rendered":"

[vc_row][vc_column width=”3\/4″][vc_custom_heading text=”About Joyzyme Group Limited” css=””][vc_custom_heading text=”Technology Embraces Love and Future” font_container=”tag:h3|text_align:left” css=”.vc_custom_1770101406961{margin-top: 20px !important;}”][vc_column_text css=”.vc_custom_1770348390575{margin-top: 20px !important;}”]The Group is a biomedical enterprise listed on the Growth Enterprise Market (GEM) of The Stock Exchange of Hong Kong Limited. It integrates high-end medical device research and development, precision manufacturing, and biotechnology services, with a long-term focus on the fields of assisted reproduction and reproductive health. The Group is committed to enhancing clinical value and public health standards through technological innovation.<\/p>\n

We possess a professional R&D team with an international perspective and have established long-term cooperative relationships with numerous leading hospitals and medical institutions, forming a complete translational system of “Research \u2013 Clinical \u2013 Product \u2013 Market”. Leveraging a mature portfolio of commercialized in vitro diagnostic reagent products, the Group has built a high level of trust within the procurement systems of medical institutions and has ranked among the top three major manufacturers in the mainland China market for male infertility in vitro diagnostic reagents. In addition, the Group was recognized as a “National High-Tech Enterprise” in 2011.<\/p>\n

In terms of its technological pathway, the Group takes its independently developed traditional Chinese medicine enzyme transformation technology as the core, integrating modern enzyme-based science and technology to establish a unique full-cycle health management system of “Prevention \u2013 Conditioning \u2013 Treatment” expanding application scenarios in precision medicine and personalized health management.<\/p>\n

The Group’s Canada-originated scientific research and industrial platform integrates R&D and production standards with a global vision, driving upgrades in product and service quality within the reproductive health sector.<\/p>\n

Looking ahead, the Group will continue to invest in the research and development of biotechnology products, actively introduce advanced international technologies, and expand its business layout along the industrial chain, creating sustainable value in life sciences and health for society through outstanding scientific research capabilities[\/vc_column_text][\/vc_column][vc_column width=”1\/4″][vc_single_image image=”5708″ img_size=”medium” alignment=”center” css=””][\/vc_column][\/vc_row][vc_row full_width=”stretch_row_content_no_spaces” css=”.vc_custom_1769066885857{margin-top: 30px !important;}”][vc_column][vc_single_image image=”5305″ img_size=”full” css=”” lazy_loading=”true”][\/vc_column][\/vc_row][vc_row bg_type=”image” parallax_style=”vcpb-vz-jquery” bg_image_new=”id^3469|url^https:\/\/joyzymebiotech.com\/wp-content\/uploads\/2026\/01\/dnabg-scaled.jpg|caption^null|alt^null|title^Web|description^null” css=”.vc_custom_1767948239131{padding-bottom: 50px !important;}” row_title=”\u7ba1\u7406\u5718\u968a”][vc_column][vc_custom_heading text=”The Management” font_container=”tag:h2|text_align:center” css=””][vc_custom_heading text=”Executive Directors” font_container=”tag:h3|text_align:left|color:%23FFFFFF” css=”.vc_custom_1768198862426{background-color: #1E73BE !important;}”][vc_row_inner][vc_column_inner width=”1\/4″][vc_custom_heading text=”Dr. Zhou Xunyong” font_container=”tag:h5|text_align:left” css=””][vc_column_text css=””](Co-Chairman)[\/vc_column_text][\/vc_column_inner][vc_column_inner width=”1\/4″][vc_custom_heading text=”Ms. Zhang Yujing” font_container=”tag:h5|text_align:left” css=””][vc_column_text css=””](Co-Chairman)[\/vc_column_text][\/vc_column_inner][vc_column_inner width=”1\/4″][vc_custom_heading text=”Mr. Zhang Chunguang” font_container=”tag:h5|text_align:left” css=””][\/vc_column_inner][vc_column_inner width=”1\/4″][vc_custom_heading text=”Mr. Poon Lai Yin Michael” font_container=”tag:h5|text_align:left” css=””][\/vc_column_inner][\/vc_row_inner][vc_custom_heading text=”Non-Executive Directors” font_container=”tag:h3|text_align:left|color:%23FFFFFF” css=”.vc_custom_1768383816268{background-color: #1E73BE !important;}”][vc_row_inner][vc_column_inner width=”1\/4″][vc_custom_heading text=”Dr. Bu Su” font_container=”tag:h5|text_align:left” css=””][\/vc_column_inner][vc_column_inner width=”1\/4″][vc_custom_heading text=”Dr. Xu Ming” font_container=”tag:h5|text_align:left” css=””][\/vc_column_inner][vc_column_inner width=”1\/4″][\/vc_column_inner][vc_column_inner width=”1\/4″][\/vc_column_inner][\/vc_row_inner][vc_custom_heading text=”Independent Non-Executive Directors” font_container=”tag:h3|text_align:left|color:%23FFFFFF” css=”.vc_custom_1768198978067{background-color: #1E73BE !important;}”][vc_row_inner][vc_column_inner width=”1\/4″][vc_custom_heading text=”Dr. Chow Kwok Fai Joseph” font_container=”tag:h5|text_align:left” css=””][\/vc_column_inner][vc_column_inner width=”1\/4″][vc_custom_heading text=”Ms. Wang Yachun” font_container=”tag:h5|text_align:left” css=””][\/vc_column_inner][vc_column_inner width=”1\/4″][vc_custom_heading text=”Mr. Tsui Wing Tak” font_container=”tag:h5|text_align:left” css=””][\/vc_column_inner][vc_column_inner width=”1\/4″][\/vc_column_inner][\/vc_row_inner][\/vc_column][\/vc_row][vc_row disable_element=”yes” css=”.vc_custom_1769068414184{padding-right: 100px !important;padding-left: 100px !important;}” row_title=”\u767c\u5c55\u6b77\u7a0b”][vc_column][vc_custom_heading text=”Milestones” font_container=”tag:h2|text_align:center” css=””]

\"timeline_pre_loader\"<\/div>
<\/span><\/div>
<\/div>\n\t\t\t\t
1992<\/span><\/div>
<\/div>
<\/s><\/l><\/div>
<\/div> <\/div>
\n\t\t\t\t\t\t\t

1992<\/h3>
Shenzhen Huakang
\nwas established in the PRC<\/div><\/div> <\/div><\/div>
<\/div>
<\/s><\/l><\/div>
<\/div> <\/div>
\n\t\t\t\t\t\t\t

2004<\/h3>
Started the R&D of male
\nfertility IVD reagents<\/div><\/div> <\/div><\/div>
<\/div>
<\/s><\/l><\/div>
<\/div> <\/div>
\n\t\t\t\t\t\t\t

2007<\/h3>
Our EBV antibody detection reagent obtained the first product registration certificate from CFDA<\/div><\/div> <\/div><\/div>
<\/div>
<\/s><\/l><\/div>
<\/div> <\/div>
\n\t\t\t\t\t\t\t

2008<\/h3>
Our male fertility IVD reagent obtained the first product registration certificate from CFDA and was commercially launched in the PRC. Our EBV antibody detection reagent was commercially launched in the PRC.<\/div><\/div> <\/div><\/div>
<\/div>
<\/s><\/l><\/div>
<\/div> <\/div>
\n\t\t\t\t\t\t\t

2011<\/h3>
Was granted the status of \u201cHigh and New Technology Enterprise\u201d(\u570b\u5bb6\u9ad8\u65b0\u6280\u8853\u4f01\u696d) by the relevant governmental
\nauthorities in the PRC<\/div><\/div> <\/div><\/div>
<\/div>
<\/s><\/l><\/div>
<\/div> <\/div>
\n\t\t\t\t\t\t\t

2012<\/h3>
Started the R&D of parasite antibody detection reagents<\/div><\/div> <\/div><\/div>
<\/div>
<\/s><\/l><\/div>
<\/div> <\/div>
\n\t\t\t\t\t\t\t

2013<\/h3>
Our parasite antibody detection reagent obtained the first product registration certificate from CFDA and was commercially launched in the PRC<\/div><\/div> <\/div><\/div>
<\/div>
<\/s><\/l><\/div>
<\/div> <\/div>
\n\t\t\t\t\t\t\t

2014<\/h3>
One of our parasite antibody detection reagents received approval for manufacture and sale in the PRC from the CFDA<\/div><\/div> <\/div><\/div>
<\/div>
<\/s><\/l><\/div>
<\/div> <\/div>
\n\t\t\t\t\t\t\t

2016<\/h3>
Moved to a new production plant at Kui Xin Community, Kui Chong Office, Dapeng New District, Shenzhen, the PRC<\/div><\/div> <\/div><\/div>
<\/div>
<\/s><\/l><\/div>
<\/div> <\/div>
\n\t\t\t\t\t\t\t

2018<\/h3>
Successfully listed on HKEx GEM Board<\/div><\/div> <\/div><\/div><\/div><\/div>[\/vc_column][\/vc_row]<\/p>\n<\/div>","protected":false},"excerpt":{"rendered":"

[vc_row][vc_column width=”3\/4″][vc_custom_heading text=”About Joyzyme Group Limited” css=””][vc_custom_heading text=”Technology Embraces Love and Future” font_container=”tag:h3|text_align:left” css=”.vc_custom_1770101406961{margin-top: 20px !important;}”][vc_column_text css=”.vc_custom_1770348390575{margin-top: 20px !important;}”]The Group is a biomedical enterprise listed on the Growth Enterprise Market (GEM) of The Stock Exchange of Hong Kong Limited. It integrates high-end medical device research and development, precision manufacturing, and biotechnology services, with a long-term…<\/p>\n","protected":false},"author":1,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"footnotes":""},"class_list":["post-3027","page","type-page","status-publish","hentry","description-off"],"_hostinger_reach_plugin_has_subscription_block":false,"_hostinger_reach_plugin_is_elementor":false,"_links":{"self":[{"href":"https:\/\/joyzymebiotech.com\/en\/wp-json\/wp\/v2\/pages\/3027","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/joyzymebiotech.com\/en\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/joyzymebiotech.com\/en\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/joyzymebiotech.com\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/joyzymebiotech.com\/en\/wp-json\/wp\/v2\/comments?post=3027"}],"version-history":[{"count":27,"href":"https:\/\/joyzymebiotech.com\/en\/wp-json\/wp\/v2\/pages\/3027\/revisions"}],"predecessor-version":[{"id":5842,"href":"https:\/\/joyzymebiotech.com\/en\/wp-json\/wp\/v2\/pages\/3027\/revisions\/5842"}],"wp:attachment":[{"href":"https:\/\/joyzymebiotech.com\/en\/wp-json\/wp\/v2\/media?parent=3027"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}